Shingles Vaccine – CRI Report https://www.cri-report.com market research vender! Mon, 25 Jul 2022 13:21:11 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Shingles Vaccine – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Shingles Vaccine Market 2022-2031 https://www.cri-report.com/investigation-report-on-chinas-shingles-vaccine-market-2022-2031/ https://www.cri-report.com/investigation-report-on-chinas-shingles-vaccine-market-2022-2031/#respond Mon, 25 Jul 2022 13:16:10 +0000 https://www.cri-report.com/?post_type=product&p=24349 According to CRI's market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY19 million(US$2.85 million), and its annual sales volume reached nearly 12,000 doses.

The post Investigation Report on China’s Shingles Vaccine Market 2022-2031 first appeared on CRI Report.

]]> The trade name of shingles vaccine (recombinant zoster vaccine) is SHINGRIX, which was developed by GlaxoSmithKline. Its product was firstly approved in China in 2020. Shingles vaccine is suitable for adults aged 50 years and over to protect against shingles (herpes zoster). The recombinant zoster vaccine has been listed in the Chinese market. By July 2022, GlaxoSmithKline Biologicals is the only manufacturer in the Chinese Shingles Vaccine market.

According to CRI’s market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY19 million(US$2.85 million), and its annual sales volume reached nearly 12,000 doses. Therefore, the development prospects are quite good.

According to CRI analysis, from 2022 to 2031, as Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase.

 

Topics Covered:

  • The impact of COVID-19 on China’s Shingles Vaccine market
  • Sales volume and value of China’s Shingles Vaccine 2020-2021
  • Sales volume and value of Shingles Vaccine by regions in China 2020-2021
  • Competitive landscape of China’s Shingles Vaccine market
  • Prices of Shingles Vaccine in China
  • Prices of Shingles Vaccine in China by regions in China
  • Analysis on factors affecting the development of China’s Shingles Vaccine market
  • Prospect of China’s Shingles Vaccine market from 2022 to 2031

The post Investigation Report on China’s Shingles Vaccine Market 2022-2031 first appeared on CRI Report.

]]> https://www.cri-report.com/investigation-report-on-chinas-shingles-vaccine-market-2022-2031/feed/ 0 Investigation Report on China’s Shingles Vaccine Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-shingles-vaccine-market-2021-2025/ Fri, 21 May 2021 06:26:16 +0000 https://www.cri-report.com/?post_type=product&p=11420 since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY2 million, and its annual sales volume reached 1,745 doses.

The post Investigation Report on China’s Shingles Vaccine Market 2021-2025 first appeared on CRI Report.

]]> Description
The trade name of Shingles Vaccine is SHINGRIX, which was developed by GlaxoSmithKline. Its product was firstly approved in China in 2020. Recombinant zoster vaccine is suitable for adults aged 50 years and over to protect against shingles (herpes zoster). The recombinant zoster vaccine has been listed in the Chinese market. By 2020, Glaxo SmithKline Biologicals is the only manufacturer in the Chinese Shingles Vaccine market.

According to CRI’s market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY2 million, and its annual sales volume reached 1,745 doses. Therefore, the development prospects are quite good.

According to CRI analysis, from 2021 to 2025, as Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase.

Topics Covered:
-The impact of COVID-19 on China’s Shingles Vaccine market
– Sales value of China’s Shingles Vaccine 2016-2020
– Competitive landscape of China’s Shingles Vaccine market
– Prices of Shingles Vaccine in China
– Prices of Shingles Vaccine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Shingles Vaccine market
– Prospect of China’s Shingles Vaccine market from 2021 to 2025

The post Investigation Report on China’s Shingles Vaccine Market 2021-2025 first appeared on CRI Report.

]]>